Veskeran Tablet 5 mg (Solifenacin Succinate)

Adult dose

The usual recommended dose for adults (including older adults) is 5mg once daily. If necessary, the dose may be increased to a maximum of 10mg once daily. This medicine may be taken with or without food and should be swallowed whole with water. The dosage regimen must be adjusted for the following patients. 1. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance>30ml/min). Use with caution in patients with severe renal impairment (creatinine clearance≤30ml/min), and do not exceed 5mg once daily. 2. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. Use with caution in patients with moderate hepatic impairment (Child-Pugh class B), and do not exceed 5mg once daily. 3. Patients taking a strong cytochrome P450 3A4(CYP3A4) inhibitor For patients taking ketoconazole or another strong CYP3A4 inhibitor (e.g., ritonavir, nelfinavir, itraconazole), limit the maximum daily dose to 5mg.

This drug alleviates symptoms of overactive bladder. However, it should not be used by individuals with urinary retention symptoms, severe gastrointestinal disorders such as toxic megacolon, severe myasthenia gravis patients, patients with narrow-angle glaucoma, and those with known allergies to this drug or its components. Additionally, it should not be administered to patients receiving hemodialysis, those with severe liver or kidney dysfunction, and individuals with certain genetic metabolic disorders. This medication should be cautiously used in individuals at risk for urinary retention or with obstructive gastrointestinal diseases or decreased gastrointestinal motility, and dosage adjustments may be necessary for those with moderate to severe renal or hepatic impairment. In particular, the maximum dosage should be limited when taken with strong CYP3A4 enzyme inhibitors. Side effects such as dry mouth, constipation, blurred vision, urinary retention, dry eyes may occur while using this medication, and the frequency of side effects increases with higher doses. Additionally, serious allergic reactions such as angioedema or anaphylaxis may occur rarely, requiring immediate discontinuation of the drug and medical attention if symptoms develop. Caution should be taken when driving or operating machinery due to symptoms such as drowsiness or blurred vision. Drug interactions may enhance the effects or worsen the side effects when used with other anticholinergic medications, and may reduce the effectiveness of drugs that increase gastrointestinal motility. This medication is metabolized by CYP3A4 enzymes, so caution is required when co-administering strong CYP3A4 inhibitors or inducers. The safety of this drug has not been established during pregnancy, so caution is advised if administered, and it should be avoided during breastfeeding as it may be excreted in breast milk and harm the infant. Safety and effectiveness in pediatrics have not been established, so its use is not recommended. In the case of overdose, central nervous system symptoms, blurred vision, thirst may occur, and appropriate emergency treatment may be necessary. Patients with heart diseases or those at risk of QT prolongation should be particularly cautious of cardiac side effects in cases of overdose.

• Dry mouth
• constipation
• blurred vision
• urinary retention
• dry eyes
• fecal impaction
• colonic obstruction
• intestinal obstruction
• angioedema
• nausea

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is recommended to store it at room temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the drug's efficacy for a longer period.

Appearance

Bright yellow round film-coated tablet

Package unit

100 tablets/PTP [(10 tablets/PTP × 10)], 100 tablets/bottle